Simona Lamba

Simona Lamba

Auto-generated profile, based on publicly available information

Simona Lamba

University of Torino Medical School

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
BMBenedetta Mussolin
Benedetta Mussolin
MBMichela Buscarino
Michela Buscarino
GCGiorgio Corti
Giorgio Corti
ACAndrea Cassingena
Andrea Cassingena
ABAlberto Bardelli
Alberto Bardelli

27 October 2010 in JAMA
Verified
Journal Article
Open access
PDF file
WRWendy De Roock
Wendy De Roock
DJDerek J. Jonker
Derek J. Jonker
Federica Di NicolantionioFederica Di Nicolantionio
Federica Di Nicolantionio
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
DTDongsheng Tu
Dongsheng Tu
STSabine Tejpar
Sabine Tejpar
Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors (NCBI Entrez Gene 3845) do not benefit from the anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab.1 These retrospective analyses were performed independently, and for each analysis, KRAS wild-type vs mutant were studied grouping codons 12 and 13 mutations together, without subgroup analysis. Health authorities in the United States and Europe have indicated that patients with KRAS codon 12– or KRAS codon 13–mutated tumors should not receive cetuximab or panitumumab.2-4

29 November 2017 in Nature
Verified
Journal Article
Closed access
PDF file
Giovanni GermanoGiovanni Germano
Giovanni Germano
SLSimona Lamba
Simona Lamba
GRGiuseppe Rospo
Giuseppe Rospo
LBLudovic Barault
Ludovic Barault
AMAlessandro Magrì
Alessandro Magrì
ABAlberto Bardelli
Alberto Bardelli

20 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
ASAlberto Sogari
Alberto Sogari
NRNicole M. Reilly
Nicole M. Reilly
SASabrina Arena
Sabrina Arena
ABAlberto Bardelli
Alberto Bardelli
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458

31 December 2008 in Human Mutation
Verified
Journal Article
Open access
PDF file
FBFonnet E. Bleeker
Fonnet E. Bleeker
SLSimona Lamba
Simona Lamba
SLSieger Leenstra
Sieger Leenstra
DTDirk Troost
Dirk Troost
THTheo Hulsebos
Theo Hulsebos
ABAlberto Bardelli
Alberto Bardelli
Systematic sequence profiling of the Glioblastoma Multiforme (GBM) genome has recently led to the identification of somatic mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Interestingly, only the evolutionarily conserved residue R132 located in the substrate binding site of IDH1 was found mutated in GBM. At present, the occurrence and the relevance of p.R132 (IDH1R132) variants in tumors other than GBMs is largely unknown. We searched for mutations at position R132 of the IDH1 gene in a panel of 672 tumor samples. These included high‐grade glioma, gastrointestinal stromal tumors (GIST), melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, prostate, and thyroid carcinoma specimens. In addition, we assessed a panel of 84 cell lines from different tumor lineages. Somatic mutations affecting the IDH1R132 residue were detected in 20% (23 of 113) high‐grade glioma samples. In addition to the previously reported p.R132H and p.R132S alleles, we identified three novel somatic mutations (p.R132C, p.R132G, and p.R132L) affecting residue IDH1R132 in GBM. Strikingly, no IDH1 mutations were detected in the other tumor types. These data indicate that cancer mutations affecting IDH1R132 are tissue‐specific, and suggest that it plays a unique role in the development of high‐grade gliomas. Hum Mutat 30, 7–11, 2009.

4 February 2010 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
FBFonnet E. Bleeker
Fonnet E. Bleeker
NANadia A. Atai
Nadia A. Atai
SLSimona Lamba
Simona Lamba
AJArd Jonker
Ard Jonker
DRDenise Rijkeboer
Denise Rijkeboer
CNCornelis Van Noorden
Cornelis Van Noorden
Somatic mutations in the isocitrate dehydrogenase 1 gene (IDH1) occur at high frequency in gliomas and seem to be a prognostic factor for survival in glioblastoma patients. In our set of 98 glioblastoma patients, IDH1 R132 mutations were associated with improved survival of 1 year on average, after correcting for age and other variables with Cox proportional hazards models. Patients with IDH1 mutations were on average 17 years younger than patients without mutation. Mutated IDH1 has a gain of function to produce 2-hydroxyglutarate by NADPH-dependent reduction of α-ketoglutarate, but it is unknown whether NADPH production in gliomas is affected by IDH1 mutations. We assessed the effect of IDH1 R132 mutations on IDH-mediated NADPH production in glioblastomas in situ. Metabolic mapping and image analysis was applied to 51 glioblastoma samples of which 16 carried an IDH1 R132 mutation. NADP+-dependent IDH activity was determined in comparison with activity of NAD+-dependent IDH and all other NADPH-producing dehydrogenases, glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, malate dehydrogenase, and hexose-6-phosphate dehydrogenase. The occurrence of IDH1 mutations correlated with approx. twofold diminished NADP+-dependent IDH activity, whereas activity of NAD+-dependent IDH and the other NADP+-dependent dehydrogenases was not affected in situ in glioblastoma. The total NADPH production capacity in glioblastoma was provided for 65% by IDH activity and the occurrence of IDH1 R132 mutation reduced this capacity by 38%. It is concluded that NADPH production is hampered in glioblastoma with IDH1 R132 mutation. Moreover, mutated IDH1 consumes rather than produces NADPH, thus likely lowering NADPH levels even further. The low NADPH levels may sensitize glioblastoma to irradiation and chemotherapy, thus explaining the prolonged survival of patients with mutated glioblastoma.